Cell line · CVCL_8792
MM1.S
Cancer cell line, Homo sapiens. Plasma cell myeloma. 75 papers.
4 sourcescell-lines-2026-11-14-0.1.0
Download JSON
Cite this record
ConductScience Library. MM1.S. Cell lines, record CVCL_8792. Release cell-lines-2026-11-14-0.1.0, 14 Nov 2026. https://conductscience.org/library/cell-lines/CVCL_8792
On this page
Cell line
As Cellosaurus gives it.
- Name
- MM1.S
- Accession
- CVCL_8792
- RRID
- RRID:CVCL_8792
- Synonyms
- MM.1S, MM1-S, MM-1S, MM1S
- Species
- Homo sapiens (Human)
- Sex
- Female
- Age at sampling
- 45Y
- Category
- Cancer cell line
- Diseases
- Plasma cell myeloma (NCIt C3242); Multiple myeloma (ORDO Orphanet_29073)
- Derived from
- Peripheral blood (in situ)
- Cell type
- Plasma cell
- Parent
- MM.1 (CVCL_5801)
- Entry created
- 2012-06-06
- Entry updated
- 2026-06-25
Source Cellosaurus
Problems0
Cellosaurus records no problem for this cell line.
None in this release.
Papers75
| Paper | Journal | Year | How we know | Retracted | Source |
|---|---|---|---|---|---|
| Unc-51 like kinase 3 (ULK3) contributes to autophagy and cell survival in multiple myeloma. | Nat Commun | 2026 | Its Methods give the RRID and name the line | PubMed | |
| APRIL-driven BCMA/TACI dual-targeted ligand-drug conjugates for selective and potent therapy of multiple myeloma. | Acta Pharm Sin B | 2026 | Its Methods give the RRID and name the line | PubMed | |
| TP53 mutation drives unique transcriptional and functional vulnerabilities independent of del(17p) in multiple myeloma. | iScience | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Schlafen 11 Is Overexpressed in Multiple Myeloma and Undergoes Nucleolar Translocation in Response to Bortezomib. | Cancer Res Commun | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Inhibition of Fibroblast Growth Factor Receptor 3 Signaling by Ponatinib Reduces Growth and Cytokine Production of Multiple Myeloma Cells. | Int J Mol Sci | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Base Editing of TIGIT Reprograms CD155 Signaling in Natural Killer Cells to Enhance Cancer Immunotherapy Efficacy. | Cancer Res | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Obesity Accelerates Multiple Myeloma Progression in Certain Mouse Models and in Humans. | Cancer Prev Res (Phila) | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Targeting BCMA in multiple myeloma with a trifunctional NK cell engager. | Cell Rep Med | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Anti-myeloma activity of the CXCR4 antagonist WZ811. | J Mol Med (Berl) | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Targeting PRKCN, an Essential Driver Orchestrating mTOR-IRF4 Axis Independently of Kinase Activity, in Multiple Myeloma. | Adv Sci (Weinh) | 2026 | Its Methods give the RRID and name the line | PubMed |
1 to 10 of 75
See all 75 papersRelatives7
| Relation | Cell line | Accession | Problem | Source |
|---|---|---|---|---|
| Parent | MM.1 | CVCL_5801 | Cell lines | |
| Derived from it | BPS Bioscience MM.1S TNFRSF17 KO | CVCL_E8DM | Cell lines | |
| Derived from it | EDITGENE MM.1S-Cas9 | CVCL_F5PJ | Cell lines | |
| Derived from it | EDITGENE MM.1S-CopGFP | CVCL_F5ZH | Cell lines | |
| Derived from it | EDITGENE MM.1S-FLUC | CVCL_F5S0 | Cell lines | |
| Derived from it | HyCyte MM.1S-Luc-GFP | CVCL_E3I2 | Cell lines | |
| Derived from it | MM.1S-luc | CVCL_B7F7 | Cell lines |
Cell banks4
| Cell bank | Catalog number | Status | Source |
|---|---|---|---|
| ATCC | CRL-2974 | ATCC | |
| CLS | 305304 | CLS | |
| EDITGENE | EDC00189 | EDITGENE | |
| IZSLER | BS TCL 237 | Cellosaurus |
Data dates
The date of each source this release read.
Sources 4
- CellosaurusCC BY 4.0, with credit to Cellosaurus (SIB)
- PubMed Central's articlesTitles shown only for CC0, CC BY and public domain articles
- NLM's PMC Article DatasetsCourtesy of NLM, which does not endorse this database
- PubMedNLM's terms
Each source's terms
- CellosaurusCC BY 4.0. Cellosaurus's README: "we have chosen to apply the Creative Commons Attribution 4.0 International (CC BY 4.0) license to Cellosaurus (https://creativecommons.org/licenses/by/4.0/). This means that you are free to copy and redistribute Cellosaurus in any medium or format. You can remix, transform, and build upon Cellosaurus for any purpose, even commercially. You must give appropriate credit, provide a link to the license, and indicate if changes were made." Copyright (c) CALIPHO group, SIB Swiss Institute of Bioinformatics. Read on 14 Nov 2026 at https://ftp.expasy.org/databases/cellosaurus/README
- PubMed Central's articlesEach article's own license. Its words show only under CC0, CC BY or public domain
- NLM's PMC Article DatasetsNLM's PMC Article Datasets on AWS, https://registry.opendata.aws/ncbi-pmc. Its terms: users "acknowledge NLM as the source of the data in a clear and conspicuous manner", do not use the PubMed Central wordmark or the PMC logo, do not "indicate or imply that NLM/NIH/HHS has endorsed" a product, and "only distribute data that are licensed for redistribution". Each article keeps its own license: https://pmc.ncbi.nlm.nih.gov/about/copyright/
- PubMedNLM's terms
Cellosaurus, SIB Swiss Institute of Bioinformatics, https://www.cellosaurus.org, CC BY 4.0. Its problem notes are given in its own words.
For software
Read this cell line from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/cell-lines/v1/CVCL_8792
GET https://conductscience.org/api/cell-lines/v1/CVCL_8792/papers?page=2